MOA of Drugs and SE Flashcards
Cyclophosphamide
Alkylating agent: Cross links DNA to impede marrow formation
SE: marrow aphasia, haemorrhagic cystitis, cardiomyopathy and hair loss
Chlorambucil
Alkylating agent: cross links DNA to impede RNA formation
SEs: marrow aphasia, hepatic toxicity, dermatitis, alopecia
Busulphan
Alkylating agent: cross links DNA to impede RNA formation
SEs: marrow aphasia, pulmonary fibrosis, hyperpigmentation, seizures, hepatic toxicity and alopecia
Melphalan
Alkylating agent: cross links DNA to impede RNA formation
SEs: marrow aphasia, alopecia
Bendamustine
Alkylating agent: cross links DNA to impede RNA formation.
Also purine nucleoside analogue
SE: myelosuppression
Hudroxycarbamide
Antimetabolite: inhibitor ribonucleotide reductase
SE: pigmentation, nail dystrophy, skin keratosis, epitheliomas.
Methotrexate
Antimetabolite: inhibit pyramidine or purine synthesis or incorporation into dna
SEs: mouth ulcers, gut toxicity
Cytosine arabinoside/cytarabine (ara-c)
Antimetabolite: inhibits dna synthesis
SEs: cerebellar toxicity and conjunctivitis
6 mercaptopurine/thioguanine
Antimetabolite: purine analogue
SEs: jaundice and gut toxicity
Clofarabine
Antimetabolite: purine analogue
SEs: myelosupression
Fludarabine, 2-CDA, deoxycoformycin (pentostatin)
Antimetabolite: purine analogues: inhibit adenosine deaminase or purine Pathways
SEs: immunsupression (low CD4 counts), renal and neurotoxicity
Daunorubicin, idarubicin, mitoxantrone
Cytotoxic antibiotics: Anthracyclines
Bind DNA and interfere with mitosis
SEs: cardiac toxicity and hair loss
Bleomycin
Cytotoxic antibiotics: inducer DNA breaks
SEs: pulmonary fibrosis, skin pigmentation
Amasacrine (m-AMSA)
Cytotoxic antibiotics: topoisomerase inhibitor
SEs: hair loss and mucositis
Vincristine and vinblastine
Cytotoxic antibiotics: spindle damage
SEs: neuropathy (peripheral/bladder/gut)
Etoposide
Cytotoxic antibiotics: mitotic inhibitor
SEs: hair loss and oral ulceration
Azacitidine and decitabine
Epigenetic modifier: hypomethylating agent
Inhibit DNA methyltransferase
SEs: myelosuppression and injection site reactions
Pabinostat and romidepsin
Epigenetic modifier: histone deacetylase
SEs: fatigue and thrombocytopaenia
Imatinib, dasatinib, nilotunib, bosutinib, ponatinib, asciminib
Signal transduction inhibitors: inihibiy ABL tyrosine kinase
SEs: myelosuppression, fluid retention, pancreatitis, GI disturbance, thrombosis (ponatonib
Midostaurin, gilteritnib, crenolanib, quizartinib, sorafenib
Signal transduction inhibitors: Flt3 kinase inhibitor
SEs: myelosuppression, GI upset and QTc prolongation
Ibrutinib, acalbrutinib, zanabrutinib
Signal transduction inhibitors: BTK protein inhibitor
SEs: bleeding, disease flare, arrhythmias/AF
Idelalisib, duvelisib, copanlisib
Signal transduction inhibitors: inhibit PI3K delta
SEs: colitis, atrial dysrhythmias
Ruxolitinib, pacritnib, fedratinib, momelitnib
Signal transduction inhibitors: inhibit JAK2
SEs: marrow suppression anaemia/thrombocytopenia, cytokine storm on withdrawal
Crizotinib
Signal transduction inhibitors: inhibit ALK
SEs: visual disturbance, hepatic enzyme elevation, GI effects
Gladesgib
Signal transduction inhibitors: inhibit hedgehog pathway
SEs: marrow suppression, myalgia, nausea, embryo-fetal toxicity
ATRA
Induces differentiation
SEs: deranged LFTs, pleural effusion, differentiation syndrome, leucocytosis
Arsenic trioxide
Induces differentiation or apoptosis
SEs: prolonged qtc, neuropathy, deranged lfts, hyperleucocytosis
A- interferon
ActIvation of RNAase and natural killer activity
SEs: flu like symptoms thrombocytopenia, leucopenia, weight loss
Enasidenib, ivosidenib
Inhibit mutated Isometric dehydrogenase (IDHI)
SEs: differentiation syndrome, cytopaenias
Venetoclax
Inhibit BCL2 signalling
SEs: tumour lysis, QTc
Omacetaxine
Inhibits protein translation
SEs: injection site reactions, GI effects, myelosuppression
Bortezemib, ixazomib, carfilozomib
Proteosome inhibitor
SEs: neuropathy
L asparginase, peg-asparginase
Deprive cells of asparginase
SEs: hypersensitivity, low albumin and coagulation factors, pancreatitis
Thalidomide, lenalidomide, pomalidomide
Immunomodulation, alteration of protein degradation
SEs: neuropathy, constipation, thrombosis, teratogenic
Rituximab, ofatumumab, obinutuzumab
Anti- CD20 induces apoptosis
SEs: infusion reaction, immunosuppression
Alemtuzumab
Anti CD52
lysis of target cells by complement fixation
SEs: infusion reactions, immunosuppression
Ibritumomab - zevalin
Anti-CD20 with Y radioisotope
SEs: myelosuppression, nausea
Myelotarg
Anti CD33, kills myeloid cells
SEs: myelosuppression, hepatic sinusoidal occlusive syndrome VOD
Inotuzumab - besponsa
Anti- CD22 kills neoplastic B cells
SEs: CRS, VOD
Tagraxofusp - elzonristm
Anti CD123 kills myeloid or BPCDN
SEs: oedema, capillary leak syndrome, nausea, fever, hepatotoxicity, hypoalbunaemia, myelosuppression
Blinatumomab
Bispecific CD20/CD3
SEs: ICANS, CRS
Brentuximab
Anti CD30
SEs: myelosuppr3ssion, neuropathy
Daratumumab
Anti- CD38
SEs: infusion reactions, myelosuppression, difficulty matching for transfusion
Eltozumab
Anti SLAMF7, kills malignant plasma cells
SEs: fatigue, GI effects, neuropathy, myelosuppression